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Abstract
Background: Influenza A virus has been detected in the blood of some infected individuals, and may pose a
safety concern for collection, handling and transport of specimens for epidemiological and public health
investigations if infectious virus is present in samples. Furthermore the effect of storage on virus stability and
infectivity has not been well studied.
Methods: We examined the stability of novel pandemic influenza A (H1N1) virus RNA when the virus was stored
in phosphate buffered saline (PBS), plasma, or buffy coated blood at either room temperature or 4°C using a
sensitive Taqman RT-PCR assay. We also investigated virus infectivity using the EID50 assay when virus was stored in
PBS, plasma, or buffy coats isolated from blood at 4°C.
Results: Viral RNA stability was affected by the matrix used for storage. The recovery of viral RNA was highest
when virus was stored in PBS with lower amounts being recovered from plasma and buffy coats at either room
temperature or 4°C. Incubation time did not appear to be a major factor for viral RNA stability, although there was
gradual decline after longer periods post-incubation. Both sample matrix and incubation time affected virus
infectivity. The decay in virus infectivity was greatest in PBS followed by buffy coats and plasma. Virus infectivity
was abolished in buffy coats at day 20 post-incubation when virus concentrations were low.
Conclusion: These data indicate that encapsidated viral RNA was stable overall in all three liquid matrices at room
temperature or 4°C although it was most stable in PBS; virus infectivity in buffy coats at 4°C decayed in a time
dependent manner while it remained unchanged in plasma. These findings have implications for storage, handling
and transport of blood derived samples from influenza patients for epidemiological and laboratory investigations. It
should be noted that there is little known about influenza viremia, and whether influenza viruses can be
transmitted by blood or blood derived samples.
Background
Influenza is a major cause of morbidity and mortality in
the United States and worldwide. The possibility of an
influenza pandemic has focused attention on the epide-
miology and pathophysiology of influenza, including its
potential for viremia in the acute phase of infection [1].
Influenza A viruses belong to the Orthomyxoviridae
family of RNA viruses. They contain eight segments of
negative sense RNA [2]. In April 2009, a novel
pandemic influenza A (H1N1) virus was identified in
Mexico and the United States [3]. Thus far, pandemic
H1N1 has been detected in more than 200 countries
and the strain has caused more than 17,000 deaths [4].
Early in the 1960s, viremia was found in patients
infected with influenza A virus in Asia [5,6]. Since then,
other groups have reported similar findings [6-9]. It has
also been reported that viral RNA could be detected in
the blood of humans with fatal outcomes while no viral
RNA could be detected in the blood of surviving H5N1-
infected individuals [10]. Recently, it has been reported
that pandemic influenza H1N1 RNA was detected in
14/139 patients included in a study, by RT-PCR, during
May 2009 - April 2010 in Hong Kong [11]
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from blood samples are often used for epidemiological
and public health investigations. The likelihood that
virus may be present in these samples could be a safety
concern for collection, handling and transport of speci-
mens. Additionally, if stored specimens are used for vir-
emia determinations, there is a need to know how
storage conditions affect virus stability in order to define
conditions that would adversely affect accuracy of test
results obtained using such samples. Under normal con-
ditions, whole blood is collected, stored at 2 ~ 8°C, or
processed within 6 h of collection. Although it is always
advantageous to use or process blood as soon as possi-
ble, most of the time it may be stored for weeks, or
shipped to another area for testing. In order to evaluate
virus stability and infectivity in buffy coats, we spiked
varying amounts of pandemic influenza A (H1N1) virus
in PBS, and blood derived buffy coat or plasma and held
samples under different temperature conditions. The
samples were then assayed using the Taqman PCR and




A novel pandemic influenza A (H1N1) virus stock, A/
California/04/2009 was obtained from the Centers for
Disease Control and Prevention (CDC, Atlanta, GA).
The virus was propagated in 9-11 day embryonic hen’s
eggs. The propagated virus was maintained at -80°C
until use in the study.
Determination of viral titers
Embryonated 11 day old embryonic hen’s eggs were
evaluated for viability and spray disinfected. The virus
was serially diluted from 10
-1 to 10
-8 in PBS containing
10 μg/ml gentamicin and 0.1 ml was injected into the
a l l a n t o i cc a v i t yo fe a c ho ff i v ee g g sp e rd i l u t i o n .E g g s
were incubated at 33°C for 3 days before chilling for 8 h
at 4°C. Allantoic fluids were collected from each egg
and 50 μl tested for hemagglutination with turkey ery-
throcytes (CBT Farms, Chestertown, MD). The Kärber
formula was used to calculate the EID50 for each strain
[12]. Data were expressed as 50% egg infectious dose
(EID50) per milliliter.
Preparation of virus dilutions in PBS, Buffy coats or
plasma
10 μlo f3 . 5 5×1 0
8 EID50/ml virus stock was diluted to
3.55 × 10
6,3 . 5 5×1 0
5,o r3 . 5 5×1 0
4 EID50 in 10 μlo f
phosphate buffered saline (PBS). The dilutions above
were mixed with 130 μl of PBS, human plasma or buffy
coat (from the NIH Buffy coats Center) at either room
temperature or at 4°C for different periods of time as
indicated, and tested for virus stability using real-time
PCR and infectivity using the HA activity assay
described above. Virus stability and infectivity for time
“0” indicated in the figures was tested immediately
(within 10 min) after mixture of virus and the specific
matrix.
Real-time PCR
Quantitative real-time reverse-transcriptase (RT) PCR
was also used for quantitation of virus in PBS, plasma
or buffy coats (a total of 140 μl). Viral nucleic acids
were isolated using the QIAamp Viral RNA Mini Kit
(Valencia, CA 91355) according to the manufacturer’s
protocol. We designed a set of primers and probes for
the matrix gene, M, of the novel H1N1 influenza A
virus, according to the GenBank database. The forward
primer was 5’-CGTCAGGCCCCCTCAAA-3’,a n dt h e
reverse primer was 5’- TTTCCTGCAAAGA-
CACTTTCCA-3’. The TaqMan probe was oligonucleo-
tide 5’- CGAGATCGCGCAGAGA-3’,c o u p l e dw i t ha
reporter dye [6-carboxy fluorescein] (FAM) at the 5’
end, a non-fluorescent quencher and a minor groove
binder (MGB), that served as a Tm enhancer, at the 3’
end. The nucleic acids were amplified and detected in
an automated TaqMan 7500 Analyzer by using the
QuantiTect™ Probe RT-PCR kit (Qiagen Inc., Valencia,
CA). The 25-μl PCR mixture consisted of 100 nM each
of primers and 100 nM probe. Following three thermal
steps at 55°C for 5 min, 50°C for 30 min and 95°C for
10 min, 45 cycles of two-step PCR at 95°C for 15 s and
at 60°C for 1 min were performed. The limit of detec-
tion was 1 fg of virus RNA per reaction with the Taq-
Man assay since the initial sample dilution was 1:10 (for
d e t a i ls e eA d d i t i o n a lf i l e1 ) .T h ed a t aw e r er e p r e s e n t e d
as an average of triple experiments.
Statistical analysis
The unpaired Student’s t test was used for data analyses
as indicated, and a value of p < 0.05 was considered sig-
nificant (*) and p < 0.01 (**) very significant.
Results
Viral RNA detection in virus spiked PBS, plasma or Buffy
coat held at room temperature up to 72 h
Ten fold dilutions of H1N1 virus in 10 μlo fP B Ss t a r t -
ing with 3.55 × 10
6 to 3.55 × 10
4 EID50 of H1N1 virus
in 10 μl of PBS were mixed with 130 μl of PBS, plasma,
or buffy coat separately and held for different periods of
time at room temperature. Nucleic acid was isolated
and quantitated using the TaqMan RT-PCR assay. As
s h o w ni nF i g u r e1 ,h i g h e ra m o u n t so fv i r a lR N Aw e r e
recovered from PBS relative to plasma or buffy coats,
but no significant changes were found within the group
of PBS, plasma, or buffy coats up to 72 h, suggesting
Wang et al. BMC Infectious Diseases 2011, 11:354
http://www.biomedcentral.com/1471-2334/11/354
Page 2 of 6that there is no significant H1N1 influenza RNA degra-
dation under these conditions. We also found that viral
RNA detection was greater with higher titers of virus
input in buffy coats, and there was no significant change
of viral RNA within 48 h of storage in buffy coats (Fig-
ure 1C).
Viral RNA recovery in Buffy coats stored at 4°C
Ten fold dilutions of H1N1 virus as described above
were added to 130 μl of buffy coats and stored at room
temperature, or 4 C for up to 48 h to test whether the
viral RNA is degraded in buffy coats at different incuba-
tion temperatures. As shown in Figure 2, viral RNA
yield was significantly increased at 4 C relative to room
temperature for three different concentrations of virus
incubated, although the copy number of viral RNA in
buffy coats was not significantly changed all the time up
to 48 h within each group of either room temperature
or 4°C (Figure 1A, B or 1C).
No significant change in viral RNA yield within the group
of PBS, plasma or Buffy coats at 4°C for up to 40 days
To study the recovery of viral RNA stored in buffy coats
at 4°C for different periods of time, H1N1 virus at the
concentrations noted above was mixed with 130 μlo f
buffy coats, incubated 4°C for different periods of time.
After isolation of nucleic acid and viral RNA detection
with TaqMan RT-PCR assay, viral RNA copy number
was not significantly changed during the incubation per-
iod at 4°C for all concentrations tested (Figure 3A).
We then compared viral RNA stability after incuba-
tion in either PBS, plasma, or buffy coats in the pre-
sence of 3.55 × 10
6,o r3 . 5 5×1 0
5 EID50 of H1N1 virus
at 4°C, and found a similar trend in that there was no
significant change of RNA recovery within each group
of PBS, plasma or buffy coats (Figure 3B &3C), although
there was gradual decline after a longer post-incubation
period (Figure 3B). These data suggest that incubation
time is not a major factor affecting viral RNA quantita-
tion, using RT-PCR, and TaqMan assays to detect
H1N1 viral RNA.
Virus infectivity in PBS, plasma or Buffy coats at 4°C
Given that viral RNA copy number was not significantly
affected during different periods of time, and that viral
RNA recovery was in the following order: PBS > plasma
> buffy coats, we further determined whether virus
infectivity was affected after incubation in PBS, plasma,
or buffy coats. 10 μl of PBS containing 3.55 × 10
6,o r
3.55 × 10
5 EID50 of H1N1 virus was incubated in PBS,
plasma, or buffy coats at 4°C for different periods of
time and EID50 assay was performed. We found
increased loss of infectivity when virus was stored in
PBS relative to buffy coats, or plasma for both virus
concentrations (Figure 4A &4B); virus infectivity was
Figure 1 Stability of influenza RNA at room temperature in
different matrices at different spiking concentrations. 3.55 ×
10
6, 3.55 × 10
5, or 3.55 × 10
4 EID50 of H1N1 virus in 10 μl of PBS,
diluted as stated in Materials and Methods was mixed with 130 μl
of PBS, plasma, or buffy coats for different periods of time indicated.
Real-time RT-PCR was performed with TaqMan and, the results were
shown as Ct value in RT-PCR. (A). Comparison of RNA recovery from
samples with different virus concentrations stored in PBS vs. in
plasma. (B). Comparison of RNA recovery from different virus
concentrations stored in PBS vs. buffy coats. (C). Comparison of RNA
yield from different virus concentrations stored in buffy coats.
Figure 2 Stability of influenza RNA at room temperature and 4
C when spiked into buffy coats at different concentrations. 3.55
×1 0
6 (A), 3.55 × 10
5 (B), or 3.55 × 10
4 (C) EID50 of H1N1 virus in 10
μl of PBS, diluted as stated in Materials and Methods was mixed
with 130 μl of buffy-coated buffy coats for different periods of time
indicated. Real-time RT-PCR was performed with TaqMan, and the
results were shown as Ct value in RT-PCR.
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gradual decline at lower virus concentration (3.55 × 10
5
EID50 of H1N1 virus) using the EID50 assay (Figure 4B).
At higher concentrations (3.55 × 10
6 EID50 of H1N1
virus), virus infectivity was significantly abolished in PBS
at day 10 postincubation relative to plasma and buffy
coats (Figure 4A); and loss of virus infectivity was slower
in buffy coats relative to PBS but higher than in plasma
(Figure 3A). Although infectivity loss at lower
concentrations (3.55 × 10
5 EID50 of H1N1 virus) in PBS,
or in buffy coats was reduced to zero at day 20 postin-
cubation, the loss of virus infectivity in buffy coats was
slower than in PBS at 10 day postincubation; and virus
infectivity declined only gradually when stored in
plasma, but was not abolished even at 40 day post-incu-
bation (Figure 4B). Therefore, loss of virus infectivity
was highest in PBS followed by buffy coats and plasma.
Virus in plasma showed no significant loss in infectivity.
Discussion
The possibility of an influenza pandemic has focused
attention on the epidemiology and pathophysiology of
influenza, with specific emphasis on strains of pandemic
potential. Viremia has been reported in some patients
infected with influenza A virus [5-9,11]. Therefore, sta-
bility and infectivity of influenza virus in blood samples
during collection, processing and transport is of poten-
tial concern. The novel pandemic influenza A (H1N1)
virus was used to study the effect of various storage
conditions on the ability to detect influenza A viral
RNA and virus infectivity in buffy coats relative to PBS
and plasma, because the H1N1 virus has been found
almost everywhere in the world [4].
Currently, influenza virus is detected and character-
ized by the use of real-time RT-PCR assays [13]. Virus
culture is often used to confirm the presence of infec-
tious virus in clinical samples. Rapid influenza antigen
tests have also been used to detect virus, although
their specificity has hampered widespread for influenza
diagnosis [14]. Our study focused on the use of RT-
PCR and infectivity as a measure of influenza virus sta-
bility in the blood matrices. The use of an RT-PCR
a s s a yd i r e c t e da tc o n s e r v e dr e g i o n so ft h ei n f l u e n z a
virus matrix gene [15] has proved invaluable as a
frontline screening assay that delivers rapid, specific
results. Following identification of an influenza virus
positive result for the matrix gene sequences, the iden-
tification of potential viral HA gene subtypes and
determination of their subtype is carried out using a
combination of additional RT-PCR assays and
sequence analysis [13]. In our study, we used an RT-
PCR assay to study the stability of pandemic H1N1
RNA, when stored in PBS, plasma, or buffy coats. Our
results showed that the H1N1 RNA copy numbers in
PBS, buffy coats, or plasma maintained for up to 3
days storage (at room temperature) or up to 35 days
storage (at 4 C) was relatively stable, and showed no
significant change. (Figure 1, 3), suggesting that storage
time under these conditions may not be a major issue
for viral RNA degradation. However, we found that
RNA copy number declined more significantly in buffy
coats at room temperature rather than at 4 C (Figure
2). These findings could be taken into consideration
Figure 3 Stability of influenza RNA at 4 C in different matrices
at different spiking concentrations. 3.55 × 10
6, 3.55 × 10
5, or 3.55
×1 0
4 EID50 of H1N1 virus in 10 μl of PBS diluted as stated in
Materials and Methods was mixed with 130 μl of PBS, plasma, or
buffy coats for different periods of time indicated. Real-time RT-PCR
was performed using TaqMan, the results were shown as Ct value
in RT-PCR. (A). Comparison of RNA recovery from different
concentrations of virus stored in buffy coats. (B). Comparison of
RNA recovery from 10 μl of 3.55 × 10
6 EID50 of H1N1 virus stored in
PBS, plasma, or buffy coats. (C). Comparison of RNA recovery from
10 μl of 3.55 × 10
5 EID50 of H1N1 virus stored in PBS, plasma, or
buffy coats.
Figure 4 Stability of influenza infectivity at 4 C in different
matrices at different spiking concentrations.1 0μl of 3.55 × 10
6
EID50 of H1N1 virus (A), or 10 μl of 3.55 × 10
5 EID50 of H1N1 virus
(B) diluted as stated in Materials and Methods was mixed with 130
μl of PBS, plasma, or buffy coats for different periods of time
indicated. EID50 assay were performed and data were shown as log
10 (EID50)/ml.
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matrices such as buffy coats or plasma of infected
persons.
Viral RNA copy numbers were significantly lower in
buffy coats relative to plasma, or PBS under our experi-
mental conditions and one possible reason may be due
to virus adsorption to blood components such as plate-
lets and red cells [16]. Higher temperature may cause
more virions to associate with these blood derived com-
ponents [7]. Therefore, more viral RNA was recovered
a n dd e t e c t e di nP B S .F u r t h e rs t u d yw i l lb en e e d e dt o
examine the effect of different anticoagulants in blood
collection, such as EDTA, heparin and sodium citrate,
on viral RNA recovery.
Although the RT-PCR assay is a useful tool to identify
influenza viral RNA stability, full characterization of
virus infectivity using an EID50 assay is necessary to
establish the effects of storage on influenza viruses. Our
experiments showed that virus infectivity decays at the
time-dependent manner, although viral RNA copy num-
ber was relatively stable during the experimental period.
Proteins binding to viral RNA, which are required for
infection of host cells, might be more prone to disasso-
ciation from each other or from viral RNA in PBS rela-
tive to plasma, and they may be easily bound to the
fibrin network as well which decreases their recovery
(Figure 3). For these reasons, at lower concentrations of
v i r u s ,t h e r em a yb eah i g h e rlikelihood for significant
loss of infectivity over time (comparison of Figure 4A
with 4B).
Conclusion
We have assessed the stability of novel pandemic influ-
enza A (H1N1) virus in PBS, plasma and buffy coats
subjected to conditions often encountered in specimen
handling, transport, and storage. We found that the
RNA copy number did not change significantly when
stored in PBS, buffy coats or plasma at room tempera-
ture up to 72 h or 4°C for up to 40 days. Although the
recovery of viral RNA copy number was greater in PBS
followed by plasma and buffy coats at either room tem-
perature or 4°C, loss of virus infectivity was higher in
PBS compared with buffy coats; infectivity in plasma did
not change significantly under these conditions over
time, especially at high doses of virus. We observed
good correlation between H1N1 viral load and infectiv-
i t yl o s si nP B S ,p l a s m ao rb u f f yc o a t su s i n gt h eE I D 50
assay. In conclusion, the findings of this study indicate
that conditions of storage of blood plasma and buffy
coats, including temperature and length of time could
have an impact on influenza virus infectivity in these
matrices and should be taken into consideration in
handling and transport of samples for diagnostic testing
and epidemiology studies.
Additional material
Additional file 1: Supplement. Amplification curve for A (H1N1)
influenza virus real-time RT-PCR assay. Shown are the serial dilutions of
A/California/04/2009 (H1N1) RNA (final concentrations 1 fg viral RNA per
reaction) with the FAM (novel swine-origin) probe. Reactions were run in
duplicate. The forward primer is 5’-CGTCAGGCCCCCTCAAA-3’, the reverse
primer is 5’- TTTCCTGCAAAGACACTTTCCA-3’, and the probe is 5’-
CGAGATCGCGCAGAGA-3’.
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